NCT07534241Recruiting
Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress. Findings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 9 Apr 2026
- Start date
- 2 Oct 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- University of Lahore
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07534241
What you commit to
- Study type: Interventional
- Planned participants: 102
- From 2 Oct 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- ● Diagnosed with severe cardiovascular disease, liver failure, or renal impairment.
- Pregnant or lactating women.
- Individuals currently on statins, ezetimibe, PCSK9 inhibitors, or any other lipid-lowering therapy.
- Allergic to mushrooms.
- Diagnosed with celiac disease or other chronic gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis).
- History of malignancy.
- Participation in another clinical trial within the last 3 months.
Who the study is looking for
- Adults aged 35-65 years
- BMI between 18.5 and 30 kg/m².
- Complete Blood Count test ranges, WBC \< 4,000-11,000 cells/µL, RBC Men \< 4.5-6.0 / Women 4.0-5.5 million/µL, Hemoglobin: Men \< 13.5-17.5 / Women 12.0-15.5 g/dL, Platelets \< 150,000-450,000 cells/µL.
- Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high.
- Liver function test markers, ALT \> 56 U/L, AST\>40 U/L, ALP\>147 UL.
- Inflammatory markers: CRP \>3 mg/L, - IL-6 ≥3 pg/mL, TNF-α ≥8 pg/mL.
- Elevated blood sugar levels, or hyperglycemia, refer to a typically above 126 mg/dL, fasting or 200 mg/dL post-meal.
Age in the registry: 35 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sana Noreen Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.